A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study With an Open-Label Phase to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects With Developmental and/or Epileptic Encephalopathies
Phase of Trial: Phase I/II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs TAK 935 (Primary)
- Indications Dravet syndrome; Encephalopathy; Epilepsy; Lennox-Gastaut syndrome; Tuberous sclerosis
- Focus Adverse reactions
- Sponsors Takeda
- 21 Aug 2017 According to an Ovid Therapeutics media release, first patient has been dosed, data is aexpected in 2018.
- 20 Jun 2017 Planned End Date changed from 12 Dec 2018 to 31 Dec 2018.
- 20 Jun 2017 Planned primary completion date changed from 28 Apr 2018 to 31 Jul 2018.